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Small molecule inhibitorsMonoamine oxidase B (MAO-B) plays a key role in the metabolism of dopamine, a neurotransmitter crit-
ical for the maintenance of cognitive function. Consequently, MAO-B is an important therapeutic target
for disorders characterized by a decline in dopaminergic neurotransmission, including Parkinson’s dis-
ease (PD). An emerging strategy in drug discovery is to utilize the biophysical approaches of thermal shift
and isothermal titration calorimetry (ITC) to gain insight into binding modality and identify thermody-
namically privileged chemical scaffolds. Described here is the development of such approaches for
reversible and irreversible small molecule inhibitors of MAO-B. Investigation of soluble recombinant
MAO-B revealed mechanism-based differences in the thermal shift and binding thermodynamic proﬁles
of MAO-B inhibitors. Irreversible inhibitors demonstrated biphasic protein melt curves, large enthalpical-
ly favorable and entropically unfavorable binding, in contrast to reversible compounds, which were char-
acterized by a dose-dependent increase in thermal stability and enthalpically-driven binding. The
biophysical approaches described here aim to facilitate the discovery of next-generation MAO-B
inhibitors.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction (L-3,4-dihydroxyphenylalanine) resulted in improved episodicThe central role of dopaminergic signaling in memory and cog-
nition is well established.1 Reduced dopaminergic neurotransmis-
sion can contribute to cognitive decline in disorders such as
Parkinson’s disease (PD).2 Inhibition of the key metabolic enzyme
for dopamine, monoamine oxidase B (MAO-B), is a clinically vali-
dated approach for maintaining dopaminergic signaling in PD
patients and can improve cognitive function in addition to the clas-
sical motor symptoms.3 During aging, dopamine levels decrease,
while MAO-B expression increases 3-fold.4 In addition to mono-
amine degradation, MAO-B activity results in the generation of
hydrogen peroxide which can promote oxidative stress and mito-
chondrial dysfunction during aging.5 These ﬁndings suggest that
therapeuticmaintenance of dopaminemay be a strategy to improve
cognitive function in the elderly. In support of this concept,
treatment of otherwise healthy elderly patients with L-DOPAmemory formation6 and MAO-B inhibitors have been shown to
improve memory in rodent models7–9 as well as Alzheimer’s dis-
ease (AD) patients.10,11 In addition to its well established role in
monoamine degradation, MAO-B was recently shown to play an
important role in c-aminobutyric acid (GABA)-mediated synaptic
inhibition by reactive astrocytes in mouse models of AD.12,13 For
these reasons, there has been a reemergence of drug discovery
efforts targeting MAO-B for AD and other disorders of memory
and cognition.14
Monoamine oxidases are ﬂavin-dependent enzymes responsi-
ble for the oxidative deamination of monoamine neurotransmit-
ters. The two MAO isoenzymes, MAO-A and MAO-B, share 70%
sequence identity and metabolize serotonin and dopamine, respec-
tively. Both enzymes are monotopically inserted into the outer
mitochondrial membrane by a single C-terminal hydrophobic
helix. Although MAO-B forms homodimeric structures, there is
no evidence of cross-talk between the two active sites.15 Currently,
the only FDA-approved MAO-B-selective inhibitors, selegiline
(L-deprenyl,) and rasagiline (Azilect), are irreversible, forming
covalent adducts to the ﬂavin adenine dinucleotide (FAD) cofactor
within the MAO-B active site.16–18 More recently, there has been an
effort to develop reversible MAO-B inhibitors with higher selectiv-
ity for MAO-B over MAO-A in order to circumvent off-target
Figure 1. Structures of MAO-B inhibitors.
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MAO-A in the gastrointestinal tract.19 This has resulted in next-
generation reversible MAO-B inhibitors, such as lazabemide
(Roche), EVT-302 (Evotec), saﬁnamide (Newron Pharmaceuticals),
and HT-3951 (Dart NeuroScience) entering clinical trials. Described
here is the development of biophysical approaches using isother-
mal titration calorimetry (ITC) and thermal shift which can compli-
ment traditional measures of afﬁnity and enable the discovery of
next-generation MAO-B inhibitors.
ITC allows for the complete thermodynamic characterization of
inhibitor binding by measuring the heat evolved upon complex
formation. The change in free energy (DG) upon inhibitor binding
can be deﬁned by changes in both enthalpy (DH) and entropy
(DS) and is directly related to binding afﬁnity (KD).20 Favorable
enthalpic contributions are largely driven by speciﬁc bonding net-
works mediated by hydrogen bonds, shape complementarity (van
der Waals’ interactions), and salt bridges, while favorable entropic
contributions are derived from bulk hydration effects, such as the
release of water molecules upon binding, hydrophobic interac-
tions, or an increase in the conformational ﬂexibility of the protein
or ligand.20 Retrospective studies have shown that best-in-class
drugs demonstrate improved enthalpy values relative to their
ﬁrst-in-class counterparts, supporting the concept that
enthalpically-driven compounds are preferred candidates for drug
development.21 As such, there is growing support for the notion
that thermodynamic studies should be harnessed early in drug dis-
covery to differentiate chemical scaffolds based on their enthalpic
efﬁciency.22,23
The capacity for a compound to inﬂuence the structural integ-
rity of a protein can be assessed using plate-based assays for ther-
mal stability.24 Protein thermal stability can be measured using
hydrophobic-sensitive ﬂuorophores to monitor protein unfolding
resulting from an increase in temperature using a standard quanti-
tative PCR instrument. Inhibitor binding results in a shift in the
observed melting temperature (Tm) providing additional insight
into binding modality.25 Fluorescence-based assays for thermal
stability are commonly referred to in the literature as thermal shift
assay (TSA), differential scanning ﬂuorimetry (DSF), temperature-
dependent ﬂuorescence (TdF), ThermoFluor, or protein thermal
shift (PTS). Such assays are increasingly used to characterize and
differentiate compounds during drug discovery.26
Integral membrane proteins can pose signiﬁcant challenges to
the development of thermal shift and ITC assays27 and although
MAO-B is classiﬁed as an integral membrane protein, it can be
puriﬁed in a soluble form which was crucial to enabling the bio-
physical studies described here.28 In order to guide internal efforts
to discover novel and reversible small molecule inhibitors of MAO-
B, existing MAO-B enzymatic assays were evaluated and biophysi-
cal methods for investigating the thermodynamic properties of
MAO-B inhibitors were developed. Described here is the biochem-
ical and biophysical investigation of published MAO-B inhibitors,
including the irreversible inhibitors rasagiline, selegiline, and par-
gyline and the reversible inhibitors lazabemide, Ro 16-6491, saﬁ-
namide, and pioglitazone, an anti-diabetic drug that was recently
shown to reversibly inhibit MAO-B (Fig. 1).292. Results and discussion
2.1. Biochemical analysis of MAO-B enzyme sources and
inhibitors
First, the enzymatic activity of soluble MAO-B28 was compared
to commercially available MAO-B30 using two biochemical assays,
MAO-Glo and Amplex Red, in a 384-well format. MAO-Glo is a
two-step luminescence-based assay where an MAO oxidizes anaminopropylether analog of a methyl ester luciferin precursor sub-
strate that is then converted into light by the addition of a lucifer-
ase-containing detection solution.31 The Amplex Red assay is a
ﬂuorescence-based method for measuring hydrogen peroxide for-
mation, which is a product of substrate oxidation. Hydrogen perox-
ide produced by MAO activity is then used by horseradish
peroxidase to convert non-ﬂuorescent Amplex Red to the ﬂuores-
cent product Resoruﬁn.32,33 An advantage of the MAO-Glo assay is
its large signal window and adaptability to screening in high-den-
sity microtiter plates. However, the reliance on endpoint reading
with a non-native substrate limits its use for detailed biochemical
studies. The Amplex Red assay has the advantage of using native
substrates with real-time monitoring.
Substrate saturation experiments frequently result in reaction
rates that exceed the assay linear range, this can be overlooked
when reading in endpoint mode. Therefore, the MAO-Glo substrate
saturation experiments were conducted at multiple time points to
ensure progress curve linearity to 60 min for each substrate con-
centration. Observed Km values for the MAO-Glo substrate were
1.1 (±0.07) lM for soluble and 0.6 (±0.09) lM for microsomal
MAO-B (Fig. 2A). These Km values were more potent relative to
the published value of 4 lM using microsomal MAO-B, an observa-
tion that is most likely the result of the previous study conducting
the Km assay outside of the linear range.31 Observed Km values for
2-phenylethylamine, a substrate speciﬁc for MAO-B, in the
Amplex Red assay format were 5.2 (±0.2) lM for soluble and 7.4
(±1.1) lM for microsomal MAO-B (Fig. 2B). These Km values for
2-phenylethylamine were in general agreement with the published
value of 4 lM.14
Enzyme titration studies were used to calculate speciﬁc activity
(activity per lg protein) by ﬁtting the resultant data to a linear
regression and determining the slope. These studies revealed that
soluble MAO-B is >20-fold more active per lg protein than com-
mercially available MAO-B preparations in the MAO-Glo assay
(Fig. 2C) and >100-fold more active per lg protein than commer-
cially available MAO-B preparations in the Amplex Red assay
(Fig. 2D). These differences in speciﬁc activity can mainly be attrib-
uted to purity; microsomal MAO-B was <20% pure, while soluble
MAO-B was >90% pure by SDS-PAGE analysis. However, other fac-
tors, such as basal enzyme activity and assay interference caused
by contaminating lipids and proteins in the microsomal prepara-
tions, may also have contributed to the observed differences.
Addition of detergent to assay buffers, including 0.015% (v/v)
reduced Triton X-100 or 0.8% (w/v) n-octyl b-D-glucopyranoside,
Figure 2. Biochemical analysis of soluble and microsomal MAO-B using the MAO-Glo and Amplex Red assay formats. Substrate saturation curves for (A) MAO-Glo substrate
and (B) 2-phenylethylamine substrate. Enzyme titration curves for (C) MAO-Glo assay and (D) Amplex Red assay. (B–D) Legend as depicted in (A) for soluble and microsomal
MAO-B.
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and was therefore left out of buffers used to conduct subsequent
studies. As such, the biophysical and thermodynamic studies
described below were performed with soluble human MAO-B pro-
tein in the absence of excess detergent using phosphate-buffered
saline (PBS).
Next, MAO-B inhibitor potencies were determined in the MAO-
Glo assay using both soluble and recombinant MAO-B (Table 1).
During assay development, it was observed that Ki values
decreased with increased pre-incubation time with values appear-
ing to plateau at 30 min. These ﬁndings are in agreement with
previous studies describing time-dependent inhibition of MAO-
A.34 In addition, mode of inhibition studies demonstrated that
some reversible inhibitors were competitive without pre-incuba-
tion, yet were non-competitive with pre-incubation (data not
shown). Therefore, a 30 min pre-incubation period was incorpo-
rated to achieve maximal binding and reduce Ki variability by
ensuring equilibrium conditions. It should be noted that the lower
level of detection for Ki values is limited by the enzyme concentra-
tion present in the activity assay, which was 4 nM for soluble
MAO-B. Observed Ki values for a majority of compounds were gen-
erally consistent between the two enzyme sources. However, the
structurally related compounds lazabemide and Ro 16-6491 were
15 and 25-fold less potent when using microsomal MAO-B,Table 1
Biochemical and biophysical characterization of reversible and irreversible MAO-B inhibit
Compound Microsomal Kia (nM) Soluble Kia (nM) Max DTm (C)b
Selegiline 3.9 3.3 9.9 (±0.2)*
Rasagiline 14.2 7.6 14.6 (±0.1)*
Pargyline 20.3 49.5 12.3 (±0.04)*
Saﬁnamide 16.7 5.4 6.6 (±0.03)**
Lazabemide 72.2 3.9 7.0 (±0.2)**
Ro 16-6491 996.9 32.2 4.5 (±0.5)**
Pioglitazone 270.8 199.4 2.5 (±0.5)**
Shown are potency values of MAO-B inhibitors for soluble and microsomal MAO-B us
thermodynamic parameters determined by ITC.
a Ki calculated by the Cheng–Prusoff method.
b DTm = Tm (compound)  Tm (DMSO only).
c DG = DH  TDS.
d DG = RT ln KB, KD = 1/KB; N/D, not determined.
* Max DTm (C) at 10 lM.
** Max DTm (C) at 100 lM.respectively. Excluding lazabemide and Ro 16-6491, the correla-
tion between soluble and microsomal Ki values was only 0.60. Col-
lectively, these results emphasize the superior quality of the
soluble enzyme source as some compounds, for example Ro 16-
6491, may appear signiﬁcantly less potent when using microsomal
MAO-B.
While surface plasmon resonance (SPR) is becoming the gold
standard method for high-throughput analysis of binding con-
stants (Kon and Koff), our attempts to immobilize MAO-B onto a
chip surface via amine coupling were not successful and resulted
in inactive protein. Therefore, a centrifugation-based reversibility
assay using rat brain preparations was developed in order to assess
reversibility and gain insight into relative off-rates of compounds.
MAO-B is an integral membrane protein that is in high abundance
in the brain, consequently, the insoluble fraction of rat brain
lysates is high in MAO-B activity and ideally suited for a centrifu-
gation-based assay. Because rat brain preparations are a heteroge-
neous mixture of MAO-A and MAO-B, their relative enzymatic
contributions were ﬁrst assessed using the non-selective
MAO-Glo substrate. Dose-response curves for selegiline (Fig. 3A),
an MAO-B-selective inhibitor, and clorgyline (Fig. 3B), an MAO-A-
selective inhibitor, were conducted at increasing concentrations
of clorgyline and selegiline, respectively. The individual IC50
values for selegiline (18 nM) and clorgyline (0.5 nM) were notors
DGc (kCal/mol) DHc (kCal/mol) TDSc (kCal/mol) KDd (nM)
9.9 (±0.3) 39.1 (±2.1) 29.2 (±2.3) 58.9 (±22.6)
N/D N/D N/D N/D
9.0 (±0.01) 53.6 (±17.6) 44.7 (±17.7) 275.4 (±5.1)
9.2 (±0.3) 8.8 (±0.9) 0.5 (±1.2) 187.2 (±117.2)
9.8 (±0.3) 13.8 (±1.0) 4.0 (±1.3) 66.0 (±47.9)
N/D N/D N/D N/D
N/D N/D N/D N/D
ing an MAO-Glo assay format, maximal Tm shifts using a thermal shift assay, and
Figure 4. Reversibility of MAO-B inhibitors in rat brain preparations. Rat brain
preparations were incubated with DMSO or compounds at 100  IC50 for 60 min
then subjected to a wash-centrifugation-resuspend assay with 9 successive wash
steps. Samples were taken prior to ﬁrst washing step (0) and at the 3rd, 6th, and 9th
wash step, then assayed for MAO-B activity in the Amplex Red assay format using 2-
phenethylamine as the substrate.
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curve span was decreased at high concentrations (Fig. 3A, B). The
total MAO-Glo activity (MAO-A + MAO-B) was more sensitive to
selegiline than clorgyline, indicating that MAO-B is the predomi-
nant isoform in rat brain preparations. Nonspeciﬁc inhibition of
MAO-A by selegiline became apparent at concentrations exceeding
781 nM, while inhibition of MAO-B activity was not observed for
clorgyline at concentrations up to 200 nM. The high degree of
selectivity of clorgyline in rat brain preparations was supported
by data obtained using recombinant microsomal MAO-A and
MAO-B where clorgyline was 2400-fold selective for MAO-A,
while selegiline was only 280-fold selective for MAO-B (data
not shown). Substrate saturation experiments were conducted
using the Amplex Red assay format to determine the Km values
of rat brain preparations for 2-phenylethylamine (18.4 lM) and
serotonin (96.2 lM) where observed Km values for 2-phenylethyl-
amine and serotonin were not signiﬁcantly affected by addition of
100  IC50 concentration of clorgyline and selegiline, respectively.
These rat brain preparations were used to develop an optimized
reversibility assay suitable for medium-throughput screening of
in-house compounds. Using this assay format, saﬁnamide and
lazabemide was shown to recover 31% and 74% activity after 3 suc-
cessive wash cycles, respectively, and 100% activity after 6
washes (Fig. 4). The relatively slow on-rate observed with pre-
incubation studies, that is, the requirement for 30 min pre-incu-
bation time for maximal inhibition, is complimented by a slow off-
rate observed in these reversibility studies, that is, the requirement
for 6 wash steps to recover 100% activity. These ﬁndings are most
likely a function of the deeply buried binding pocket within MAO-B
and the requirement for the gating residue isoleucine 199 to
change conformation, allowing for the occupation of both the
entrance and substrate binding cavities.35,36 Relative to alternative
reversibility methods, such as dialysis and rapid dilution, it was
found that the centrifugation-based approach was the most
reproducible and amendable to medium-throughput compound
proﬁling. Rat brain preparations consistently outperformedFigure 3. Evaluation of the relative contributions of MAO-A and MAO-B activities in
rat brain preparations. Rat brain preparations were assayed for MAO activity using
the non-selective MAO-Glo substrate in the presence of a matrix of concentrations
of clorgyline (MAO-A speciﬁc) and selegiline (MAO-B speciﬁc). (A) Selegiline dose-
response curves in the presence of increasing amounts of clorgyline (0.06–200 nM).
(B) Clorgyline dose–response curves in the presence of increasing amounts of
selegiline (0.05–50,000 nM).alternative enzyme sources, such as human platelet mitochondria
or microsomal preparations, due to their increased stability over
the course of the assay and minimal assay interference (data not
shown). The overall raw enzyme activity of DMSO control samples
from rat brain preparations was only 25% reduced over the
course of 9 wash-centrifuge-resuspend cycles.
2.2. Investigation of MAO-B inhibitors by thermal shift
Previous efforts to establish thermal shift assays for MAO-B
have resulted in the development of ThermoFAD, a method that
directly measures the intrinsic ﬂuorescence of the FAD cofactor,
which can be applied to a wide variety of ﬂavoproteins.37 Excita-
tion of FAD near the maxima of 450 nm results in ﬂuorescence
emission near the maxima of 535 nm; thermal denaturation of ﬂa-
voproteins increases this intrinsic ﬂuorescence. This label-free
method is particularly useful for identifying optimal buffer condi-
tions or characterizing ﬂavoprotein mutations. However, we found
that ThermoFAD was poorly suited for proﬁling diverse MAO-B
inhibitors, because irreversible MAO-B inhibitors signiﬁcantly alter
the absorption properties of FAD. The binding of irreversible inhib-
itors, such as rasagiline, results in covalent adduct formation
within FAD that can be detected at 414 nm (Fig. 5A); reversible
inhibitors, such as saﬁnamide, do not alter FAD absorption spectra
(Fig. 5B). High concentrations of rasagiline (>39 lM) and selegiline
(>100 lM, data not shown) were necessary to elicit a signiﬁcant
shift in the FAD absorption spectra due to the high MAO-B concen-
tration (25 lM) required to produce an adequate absorbance sig-
nal. However, in the absence of MAO-B, these concentrations did
not produce signiﬁcant absorbance peaks (Fig. 5).
In order to investigate protein stabilization upon inhibitor bind-
ing for a wide variety of reversible and irreversible MAO-B inhibi-
tors, a SYPRO orange-based thermal shift assay was developed.
Buffer components, including salt, pH, and additives, were
screened to identify optimal buffer conditions for MAO-B protein
stability. It was found that MAO-B was thermally stable in a variety
of conditions from pH 6.5–7.5 (data not shown) and that removal
of excess n-octyl b-D-glucopyranoside present in the puriﬁcation
buffer was critical to the success of this assay as the hydrophobic
environment of detergents can interfere with the ﬂuorescence
properties of the SYPRO orange dye. Ultimately, PBS was selected
to conduct additional studies because it was compatible across
multiple assay formats, such as the above mentioned biochemical
assays and ITC assays described below, it was physiologically rele-
vant, and it gave consistent thermal melt curves for a number of
compounds screened. Soluble MAO-B protein melt curves in PBS
buffer were highly reproducible and tolerant to DMSO concentra-
tions up to 10%. Although the signal window within the region of
Figure 5. UV–vis absorption spectra of bound FAD cofactor for soluble MAO-B.
Increasing concentrations (39–625 lM) of (A) rasagiline or (B) saﬁnamide were
incubated with 25 lM recombinant soluble MAO-B for 45 min prior to reading
absorption spectra. Spectra for DMSO only (DMSO) and samples at the highest
compound concentration in the absence of MAO-B are also shown (625 no MAO-B).
(B) Concentrations for saﬁnamide are as depicted in (A).
774 R.J. Rojas et al. / Bioorg. Med. Chem. 23 (2015) 770–778analysis for thermal shift curves was relatively small (1.2-fold),
the data were highly reproducible, with a mean Tm value for con-
trol samples in 10% DMSO of 53.1 (±0.3) C. This observed value
was in general agreement with the literature Tm value of 51 C
obtained by ThermoFAD and 57 C obtained by circular
dichroism.37
Thermal shift analysis of MAO-B inhibitors demonstrated prom-
inent mechanism-dependent differences in thermal melt proﬁles.
The melt curves for reversible MAO-B inhibitors were dose-depen-
dent with single-species transition phases typically seen in the lit-
erature24–26 (Fig. 6D–G) and had moderate maximal Tm shifts
(Table 1). EC50 values based on Tm shifts were 7.1 lM, 15 lM,
and 29 lM for lazabemide, saﬁnamide, and Ro 61-6491, respec-
tively, while an accurate EC50 could not be obtained for pioglitaz-
one (Fig. 6I); however, it has been our experience that maximal
DTm values are more informative than EC50 values when progress-
ing compounds (data not shown). The large differences between
EC50 values obtained by thermal shift relative to enzymatic assays,
that is, 1000-fold less potent when assessed by thermal shift, can
be attributed primarily to the large discrepancy in MAO-B protein
concentrations required for enzymatic assay (3 nM) versus thermal
shift assays (3.4 lM). It was found that compounds with low
potency, such as the irreversible inhibitors phenelzine, tranylcyp-
romine, and the reversible inhibitor 8-(3-chlorostyryl)-caffeine,
did not signiﬁcantly shift the Tm value at 100 lM, although they
were active in the soluble MAO-Glo assay with Ki values of 94,
26, and 210 nM, respectively. This is most likely due to the poor
solubility of these compounds at the higher concentrations neces-
sary to elicit a thermostablizing response.
The irreversible inhibitors rasagiline, pargyline, and selegiline
were shown to have signiﬁcantly larger maximal Tm shifts (Table 1)
and were characterized by atypical biphasic melting curves
(Fig. 6A–C). Upon examination of the thermal melt curves, it is
apparent that two protein stability states exist as distinct popula-
tions in the low (0.47–0.78 lM) and high end (3.6–10 lM) of inhib-
itor concentrations, most likely resulting from unbound and bound
forms of MAO-B, respectively. A heterogeneous population of the
two states is evident within a narrow range of intermediate
compound concentrations (1.3–2.2 lM). Melt curves within thisnarrow region appeared bifurcated, precluding the determination
of accurate Tm values and quality dose–response curve ﬁts
(Fig. 6H). It is within this intermediate concentration range that
the inhibitor concentration (1.3–2.2 lM) is approximately half of
the MAO-B concentration (3.4 lM). Interestingly, these results
are consistent with previous studies examining radicicol and
ethoxzolamide, which are non-covalent tight-binding inhibitors
of heat shock protein 90 (Hsp90) and carbonic anhydrase II (CAII),
respectively.38 Although radicicol and ethoxzolamide are non-
covalent and the ﬂuorescent probe used was 1-8-anilinonaphtha-
lene sulfonate (ANS), the results from this previous study38 are sur-
prisingly similar to the covalent MAO-B inhibitors described here.
Both demonstrate atypical biphasic melt curves occurring at ligand
concentrations that are approximately half the target protein con-
centration and exhibit large DTm values, upwards of 10 C.
The data reported here suggest that thermal shift assays using
SYPRO orange can be utilized to differentiate and prioritize revers-
ible compounds based on maximal DTm values. Additionally, this
work suggests that thermodynamic principles underlying thermal
shift assays for reversible tight-binding inhibitors may extend to
covalent inhibitors as well.
2.3. Investigation of MAO-B inhibitors by isothermal titration
calorimetry
Finally, the thermodynamics of MAO-B binding to reversible
and irreversible inhibitors were characterized using ITC. There
are few literature examples using ITC to study integral membrane
proteins, but in all such cases, detergent was required for protein
function.27 Although a comprehensive study of pH and detergent
effects on inhibitor binding is outside the scope of this report, a
series of buffers and detergent additives were tested (data not
shown). It was observed that the most consistent ITC results were
obtained using PBS in the absence of detergent, which is in agree-
ment with observations described in Sections 2.1 and 2.2. Notably,
the presence of detergent in MAO-B ITC buffers, including 0.015%
(v/v) reduced Triton X-100 or 0.8% (w/v) n-octyl b-D-glucopyrano-
side, resulted in large heats of dilution which masked heat released
upon binding, an observation previously described in the litera-
ture.27 The ability for MAO-B to remain functional in buffers lack-
ing excess detergent is most likely because MAO-B has only a
single C-terminal transmembrane helix. While this helix remains
important for the proper expression, folding, and orientation
within lipid bilayers, it has little impact on the structure and func-
tion of the distal globular catalytic domain of the mature protein.
Due to the large differential power (dP) values observed by irre-
versible MAO-B inhibitor binding, as well as high and low-fre-
quency noise encountered, it was essential to use improved
computational methods for ITC data analysis. NITPIC was used
for peak assignment of thermograms because it uses robust peak
identiﬁcation algorithms that can be user-deﬁned and allows for
the calculation statistical error measurements which are weighted
during global ﬁt analysis.39 SEDPHAT was used for global isotherm
curve ﬁt to a 1:1 bimolecular reaction model,40 while analysis
results were plotted using GUSSI (Chad Brautigam, UT Southwest-
ern). The NITPIC/SEDPHAT/GUSSI suite of programs eliminates
baseline values, as they are not essential for the global curve ﬁt;
therefore, thermogram ﬁgures lack baseline values.
Results for MAO-B compounds tested are summarized in
Table 1, with representative GUSSI plots depicted in Supplemental
ﬁgures 1–4. As may be expected, the thermodynamic parameters
for reversible and irreversible MAO-B inhibitors were markedly
different due to the fundamental differences between covalent
and non-covalent binding. Additional literature compounds were
attempted, including the irreversible inhibitor rasagiline and
reversible inhibitors Ro 16-6491 and pioglitazone. However, the
Figure 6. Evaluation of MAO-B inhibitors by thermal shift. Increasing concentrations of (A) rasagiline, (B) pargyline, (C) selegiline, (D) lazabemide, (E) Ro 16-6491, (F)
saﬁnamide, or (G) pioglitazone were incubated with soluble MAO-B for 20 min then assayed for thermal stability using a SYPRO orange-based thermal shift assay. (B,C)
Compound concentrations (0.5–10 lM) as depicted in (A). (E–G) Compound concentrations (1.7–100 lM) as depicted in (D). Dose–response curves for irreversible (H) and
reversible (I) MAO-B inhibitors.
Figure 7. Representative raw ITC injections for MAO-B inhibitors. Differential
power (dP) traces for single titrations representative of the ﬁrst 2–3 injections
(prior to saturation binding) were baseline subtracted and overlaid to highlight
temporal differences of heat release upon inhibitor binding.
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dence due to excessive noise and poor curve ﬁts. Although outside
the scope of this report, a more detailed study of buffer compatibil-
ity may be required to identify conditions that allow for the study
of additional literature MAO-B inhibitors by ITC. The calculated KD
values of compounds determined via ITC were signiﬁcantly less
potent than Ki values obtained by enzymatic analysis, although
the rank order potency was consistent. This discrepancy in poten-
cies can in part be attributed to the time-dependent nature of
MAO-B inhibition as described in Section 2.1. While the enzymatic
assay incorporates a 30 min pre-incubation period followed by a
60 min reaction with substrate, the ITC assay measures heat of
binding per injection in real-time.
Closer examination of individual titration curves reveal distinct
recovery phases after injection (Fig. 7). Selegiline, saﬁnamide, and
lazabemide displayed similar kinetics of heat release, with dP val-
ues returning to baseline on the order of 2–4 min for early injec-
tions prior to binding saturation and 5–10 min for injections near
half maximal occupancy. However, pargyline required 10 min
for baseline return during the course of the experiment. Due to
these observed broad injection peaks, the minimum integration
periods in NITPIC were manually increased from 50% to 75% of
the injection time and individual titrations were allowed to equil-
ibrate for extended periods of time. This resulted in ITC experi-
ments that lasted for 2–3 h. Additionally, pargyline peaks were
bifurcated due to an interfering endothermic heat of compound
dilution that was subsequently subtracted during data analysis.
The signiﬁcance of this ﬁnding is still under investigation.
It was observed that covalent inhibitors released signiﬁcantly
more heat upon binding MAO-B than reversible inhibitors with
DDH measures of 30.3 kCal/mol for selegiline and 44.8 kCal/mol for pargyline, both relative to saﬁnamide. Enthalpically favor-
able values stem from the formation of stable bonding networks
and in the case of selegiline and pargyline, these large enthalpy
values can be attributed to the signiﬁcant heat released upon the
formation of an N(5) cyano adduct with FAD cofactor within the
MAO-B active site. The unusually large heat released upon adduct
formation was compensated by severe entropic penalties, with
mean TDS values of +29.2 for selegiline and +44.7 kCal/mol for
pargyline. Entropically favorable values result from both solvation
and conformation components. Favorable solvation entropy values
are caused by the repulsive force of hydrophobic groups away from
solvent and their concomitant burial into hydrophobic pockets,
while favorable conformational entropy stems from an increase
in the conformational degrees of freedom. The large entropic
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a reduction in the number of reacting molecules due to covalent
fusion and the corresponding increase in conformational strain
within the protein and bound FAD cofactor. Within the active site,
selegiline41 and pargyline42 are situated within a hydrophobic cage
formed by the FAD cofactor and pi-stacked tyrosine residues 398
and 435, which lie perpendicular to the re-face of the ﬂavin ring
structure. There is signiﬁcant conformational strain on tyrosine
398 as a result of the amine bond with cysteine 397 existing in a
cis rather than trans conformation. In order for selegiline and par-
gyline to gain access to the FAD cofactor they must traverse this
region, which may impart a signiﬁcant conformational strain in
the process.41,42 Additionally, the dimethylbenzene ring and
pyrimidine ring of the bound FAD take on a distorted structure that
deviates 30 from planarity relative to the non-protein bound
conformation. While this non-planar conformation is thought to
facilitate oxidative deamidation of substrate molecules, the
requirement for selegiline and pargyline to directly engage this
strained ﬂavin ring may also incur a signiﬁcant entropic penalty.
The MAO-B active site is bifurcated and comprised of a 290 Å3
entrance cavity and 490 Å3 substrate binding cavity with the cata-
lytic FAD site buried 20 Å below the protein surface.43 A surface
exposed loop occludes the access to the entrance cavity while four
residues span the boundary between the two cavities. Both cavities
demonstrate conformational ﬂexibility and can accommodate a
large variety of substrates and inhibitors with the greatest confor-
mational change occurring with the ‘gating residue’ isoleucine 199
separating the two cavities.35,36 The time-dependent inhibition and
slow recovery of enzyme activity observed for MAO-B inhibitors in
Section 2.1 are the direct result of the inaccessible nature of the
MAO-B active site. Based on the crystal structures, saﬁnamide44
and Ro 16-6491,45 which is a close analog of lazabemide, both bind
in similar orientations. The benzyl-halide moieties are situated
within the entrance cavity and the amino groups are orientated
toward the FAD cofactor in the substrate binding cavity. However,
saﬁnamide binds in an extended conformation that is sufﬁciently
large enough to ﬁll both cavities while Ro 16-6491 only partially
ﬁlls the entrance cavity. In the saﬁnamide-bound structure, addi-
tional hydrophobic interactions within the entrance cavity results
in a more extended conformation resulting in the fusion of the
two cavities into a single extended cavity. However, in the Ro
16-6491 structure, the cavities take on a more bipartite appearance
with fewer hydrophobic interactions occurring within the entrance
cavity. These structural differences may account for some of the
observed differences in entropy values for saﬁnamide and lazabe-
mide, which have TDS values of 0.5 and +4.0, respectively.
The additional hydrophobic interactions within the entrance cavity
may impart saﬁnamide a slight entropic advantage relative to
lazabemide.
3. Conclusions
In summary, soluble andmicrosomalMAO-Bwere evaluated the
MAO-Glo andAmplex Red assay formats. SolubleMAO-Bwas signif-
icantly more active than microsomal MAO-B in both assays. A
robust reversibility assay using rat brain preparations was
described that can be used to routinely screen compounds allowing
additional insight into the relative off-rates of next-generation
reversible MAO-B inhibitors compounds, while data presented for
lazabemide and saﬁnamide can serve as a reference standard for
these studies. To gain understanding of the biophysical properties
underlying MAO-B inhibitor binding, both thermal shift and ITC
assay methodologies were developed using soluble MAO-B protein.
Both methods were able to distinguish compounds based on mech-
anism of action and can be used to further differentiate compoundsand compliment traditional measures of afﬁnity. Collectively, the
biochemical and biophysical approaches described here may facili-
tate the discovery of next-generation MAO-B inhibitors for the
treatment of diseases states characterized by reduced dopaminergic
neurotransmission, including PD, AD, and other cognitive disorders.
4. Materials and methods
4.1. Compounds
Selegiline, pargyline, Ro 16-6491, and pioglitazone were pur-
chased from Sigma Aldrich (St. Louis, MO); lazabemide was pur-
chased from Tocris Bioscience (Bristol, UK); saﬁnamide was
synthesized as previously described.46 Compound dry powders
were dissolved in 100% DMSO to a stock concentration of 10 mM
then further diluted as required.
4.2. Soluble MAO-B protein puriﬁcation
Human MAO-B was expressed in Pichia pastoris and puriﬁed in
soluble form as previously described.28 Buffer conditions for the
ﬁnal MAO-B preparation were 50 mM phosphate buffer (potassium
salt) pH 7.4, 50% glycerol, and 0.8% n-octyl b-D-glucopyranoside
detergent (w/v). Prior to experiments described below, MAO-B
protein was buffer exchanged into standard phosphate-buffered
saline (PBS) (1 mM potassium phosphate monobasic, 3 mM sodium
phosphate dibasic, 155 mM NaCl, pH 7.5) using a desalting column
(GE Healthcare Biosciences, Piscataway, NJ) to remove excess
unbound detergent. This buffer was used for all subsequent exper-
iments described here. Protein concentrations were determined
using the A280 method for an MAO-B dimer.15
4.3. Substrate Km experiments
MAO-Glo Km experiments were performed in 384-well format
using multiple reading time-points in order to monitor reaction
linearity. The MAO-Glo substrate was serially diluted and incu-
bated with either soluble (4 nM) or commercially available micro-
somal (10 lg/mL) (BD Biosciences, San Jose, CA) MAO-B and
assayed per manufacturer’s protocol (Promega, Madison, WI).
Amplex Red assays were conducted in 384-well format using reac-
tion mixture containing horseradish peroxidase (2 U/mL) (EMD
Millipore, Billerica, MA), Amplex Red (100 lM) (Life Technologies,
Grand Island, NY), and either soluble (60 nM) or microsomal
(92 lg/mL) MAO-B. The endogenous MAO-B substrate, 2-phenyl-
ethylamine (Sigma Aldrich, St. Louis, MO) or MAO-A substrate,
serotonin (Sigma Aldrich, St. Louis, MO), was serially diluted then
added to initiate the enzyme reaction. Fluorescence was measured
in real-time (kex 531 nm, kem 584 nm) to ensure reaction linearity.
The observed V0 values for each substrate concentration was deter-
mined from resultant progress curves then ﬁt to a standard
Michaelis–Menten equation (GraphPad, La Jolla, CA) in order to cal-
culate Km values. All substrate saturation experiments were con-
ducted at several enzyme concentrations to ensure Km values
were not enzyme concentration-dependent. Reported Km values
are the mean of three independent experiments.
4.4. Enzyme titration experiments
Microsomal and soluble MAO-B were serially diluted and
assayed for enzyme activity using the MAO-Glo and Amplex Red
assay formats. MAO-Glo enzyme titration experiments were per-
formed in endpoint mode using 500 nM substrate and a reaction
time of 60 min, which was optimized for assay linearity, while
Amplex Red enzyme titration experiments were conducted using
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tion 4.3. Depicted activity graphs are the mean of two independent
experiments.
4.5. MAO-Glo inhibitor Ki assay
All Ki values were determined using a 384-well MAO-Glo assay
in endpoint mode. Serially diluted compounds were pre-incubated
for 30 min at room temperature with soluble (4 nM) or microsomal
(10 lg/mL) MAO-B. MAO-Glo substrate (500 nM) was then added
to initiate the 60 min reaction and assayed as described in Sec-
tion 4.3. Data were then ﬁt to a variable slope 4-paramter sigmoid
curve (GraphPad, La Jolla, CA). Observed Ki values were calculated
using the Cheng-Prusoff method47 and are the mean of two inde-
pendent experiments.
4.6. MAO-B reversibility assay
Rat whole brain homogenates were centrifuged for 15 min at
12,000g and resuspended in 100 mM HEPES pH 7.4, 5% glycerol
prior to use. Compounds at 100  IC50 values were pre-incubated
with brain preparations (1 mg/mL) for 60 min. Samples were then
centrifuged at 12,000g for 10 min at room temperature; the
supernatants were aspirated and discarded. The remaining visible
pellet containing MAO-B was manually resuspended with 1 mL
buffer and incubated for 30 min at 37 C while constant shaking
to prevent membrane sedimentation. Samples were then subjected
to 9 repeated incubation-centrifugation-resuspension cycles. An
aliquot of sample was taken before the ﬁrst wash step, wash 0 con-
taining 100  IC50 compound concentration, and after the 3rd, 6th,
and 9th wash steps for use in an MAO-B enzyme assay. Recovered
MAO-B activity was determined after each successive wash step
using the Amplex Red assay described above (Section 4.3). Revers-
ibility was calculated by normalizing MAO-B activity values for
each wash step to Rasagiline (0% recovered activity) and DMSO
(100% recovered activity). A standard BCA protein concentration
assay was used after the 9th wash to ensure that protein concen-
trations in each sample were not signiﬁcantly affected by repeated
wash steps. Reported values are the mean of four independent
experiments.
4.7. UV–vis spectrum analysis
Recombinant soluble MAO-B (25 lM) was incubated with
increasing concentrations of compounds (39–625 lM) for 45 min
prior to measuring the UV–vis spectra from 350–525 nm using a
NanoDrop 2000 (Thermo Scientiﬁc, Wilmington, DE). Data are rep-
resentative of two independent experiments.
4.8. Thermal shift assay
The melting temperature (Tm) of MAO-B in the presence and
absence of inhibitors was determined using 96-well ﬂuores-
cence-based thermal shift assay. Compound serial dilutions were
ﬁrst pre-incubated for 20 min at 4 C with soluble MAO-B
(3.4 lM ﬁnal concentration), then 1x SYPRO orange dye (Life Tech-
nologies, Carlsbad, CA) was added and plates were centrifuged for
2 min at 1000g before being read (kex 470 ± 15 nm, kem
520 ± 15 nm) in a StepOnePlus quantitative PCR instrument (Life
Technologies, Carlsbad, CA). The thermal shift protocol consisted
of an initial temperature hold at 25 C for 2 min, followed by a tem-
perature ramp up to 80 C at a rate of 1 C/second, and ﬁnished
with a temperature hold at 80 C for 2 min; data were collected
at 0.25 C increments. Data was analyzed using the Protein Ther-
mal Shift software package (Life Technologies, Carlsbad, CA) to
determine Boltzmann Tm values using a region of analysis ofapproximately 50–70 C. All conditions were assayed in PBS buffer
with a ﬁnal concentration of 10% DMSO. DMSO only wells were
used to calculate DTm values where DTm = Tm (compound)  Tm
(DMSO only). Dose–response curves in the absence of MAO-B pro-
tein were conducted to ensure compounds did not interfere with
ﬂuorescence properties of SYPRO orange dye. In ﬁgures depicting
individual melt curves, raw data was normalized to the high and
low relative ﬂuorescence values within the region of analysis. To
determine EC50 values, data were then ﬁt to a variable slope 4-
paramter sigmoid curve (GraphPad, La Jolla, CA). Data are repre-
sentative of two independent experiments.
4.9. Isothermal titration calorimetry (ITC)
ITC data was collected using a Microcal iTC200 (GE Healthcare
Biosciences, Piscataway, NJ) at 25 C. In each ITC run, the cell con-
tained soluble MAO-B (5–10 lM) and the syringe contained com-
pound (50–200 lM). Instrument settings were optimized for each
MAO-B inhibitor to ensure that titrations yielded suitable satura-
tion curves. The volume of the ﬁrst injection of each ITC run was
<1 lL to minimize the experimental impact caused by dilution
effects that occur at the tip of the injection syringe; this injection
was excluded during analysis. The program NITPIC was used to
analyze and integrate titration peaks,39 SEDPHAT was used for glo-
bal analysis curve ﬁt to a 1:1 bimolecular interaction model,40 and
GUSSI was used to generate ITC ﬁgures (Chad Brautigam, UT South-
western). NITPIC removes baseline values prior to analysis and this
is reﬂected in the ﬁnal plots which eliminate background baseline
values. Due to wide peaks observed, minimum injection time in
NITPIC was increased from 50% to 75%. ITC values depicted are
the mean of three independent experiments.
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